Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06444256
PHASE2

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Sponsor: The University of Texas Health Science Center, Houston

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.

Official title: Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder: A Pilot Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-07-25

Completion Date

2027-01-30

Last Updated

2025-09-05

Healthy Volunteers

No

Interventions

DRUG

SUVO

Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11

DRUG

TAU

Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.

Locations (1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States